Literature DB >> 29753690

Successful Use of Bortezomib-Lenalidomide Combination as Treatment for a Patient With Plasmablastic Lymphoma.

William D Marrero1, Alexis Cruz-Chacón2, Christian Castillo2, Fernando Cabanillas2.   

Abstract

Entities:  

Keywords:  HIV negative; Non-Hodgkin's; PBL; Parotid gland; Remission

Mesh：

Substances：

Year:  2018        PMID： 29753690     DOI： 10.1016/j.clml.2018.04.011

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  4 in total

Review 1.  Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review.

Authors:  Hirotaka Mori; Masahiko Fukatsu; Hiroshi Ohkawara; Yuka Oka; Yuki Kataoka; Shunsuke Taito; Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2021-08-30       Impact factor: 2.490

2.  Plasmablastic Lymphoma, a Rare Entity in Bone Marrow with Unusual Immunophenotype and Challenging Differential Diagnosis.

Authors:  Majd Al Shaarani; Rodney E Shackelford; Samip R Master; Glenn M Mills; Yasir AlZubaidi; Ahmed Mamilly; Eric X Wei
Journal:  Case Rep Hematol       Date:  2019-09-02

3.  Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach.

Authors:  Waleed Sabry; Yue Wu; Shruthi Ganeshappa Kodad
Journal:  Curr Oncol       Date:  2022-07-18       Impact factor: 3.109

4.  Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham's Lymphangiomatosis: Review of the Literature.

Authors:  Matthew Lee; Beth A Martin; Haifaa Abdulhaq
Journal:  Case Rep Hematol       Date:  2022-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.